Novartis Updating Tekturna Label with Warnings for Diabetes, Kidney Patients. Announces Valturna Market Withdrawal
Tekturna Label Are Being Updated With Warnings. Novartis has announced that it will be making changes to the labels for Tekturna and other aliskiren-based medications regarding serious risks posed by such drugs when they are used by diabetics or patients with kidney failure who are also taking ACE Inhibitors or angiotensin receptor … [Read more...] about Novartis Updating Tekturna Label with Warnings for Diabetes, Kidney Patients. Announces Valturna Market Withdrawal
Novartis Agrees to Settle Drug Rep Overtime Lawsuit
Novartis Settle Overtime Lawsuit. After six years of litigation, Novartis Pharmaceuticals Corp. has agreed to pay $99 million to settle a class action lawsuit brought on behalf of pharmaceutical sales reps who allegedly were illegally denied overtime pay for working more than 40 hours per week. The deal has been tentatively … [Read more...] about Novartis Agrees to Settle Drug Rep Overtime Lawsuit
Elidel Side Effects May Link To Increased Cancer Lawsuits
Elidel Side Effects Injury Lawsuits. Elidel, manufactured by Novartis, was approved by the FDA in December 2001. Elidel is prescribed to treat Eczema and is also commonly prescribed off-label for psoriasis and dermatitis seborrhea. On March 10, 2005, the FDA stated that Elidel should carry a strong advisory about cancer risks. … [Read more...] about Elidel Side Effects May Link To Increased Cancer Lawsuits
Novartis as Defendant in Zofran Lawsuit
Xarelto's Manufacturers Versus Plaintiffs. Novartis Pharmaceuticals has been named alongside GlaxoSmithKline in litigation over the anti-nausea medication Zofran. Some 250 lawsuits were consolidated in the U.S. District Court of Massachusetts alleging the drug makers illegally promoted Zofran off-label for morning sickness, leading … [Read more...] about Novartis as Defendant in Zofran Lawsuit
Novartis Updating Tekturna Label with Warnings
/category/defective-drugs/tekturna Novartis Updating Tekturna Label. Novartis has announced that it will be making changes to the labels for Tekturna and other aliskiren-based medications regarding serious risks posed by such drugs when they are used by diabetics or patients with kidney failure who are also taking ACE … [Read more...] about Novartis Updating Tekturna Label with Warnings
Novartis to Suspend Marketing of Zelnorm
Novartis Suspend Drug Zelnorm. The U.S. Food and Drug Administration (FDA) notified Novartis Pharmaceuticals Corporation that the company must cease its marketing of Zelnorm (tegaserod), a prescription drug used in the treatment of constipation and irritable bowel syndrome (IBS). According to the FDA, Zelmorm has been associated with … [Read more...] about Novartis to Suspend Marketing of Zelnorm
Novartis to Stop Constipation Drug Sale
Swiss Pharmaceutical Maker Novartis AG Will Stop Selling A Drug. Swiss pharmaceutical maker Novartis AG will stop selling a drug to relieve constipation after it was linked to a higher chance of heart attack, stroke and worsening heart chest pain that can become a heart attack, federal health officials said Friday. Novartis agreed … [Read more...] about Novartis to Stop Constipation Drug Sale
Novartis recalls cough-suppressant Triaminic Vapor Patch due to health risks
Triaminic Vapor Patch Cough-Suppressant Recall. Novartis AG said it has started to recall its Triaminic Vapor Patch cough-suppressant because of potential health threat to children who might remove it and chew on the patch. Vapor Patch is widely available in the US and sold over the counter. The US Food and Drug Administration … [Read more...] about Novartis recalls cough-suppressant Triaminic Vapor Patch due to health risks
FDA Warns Consumers Not to Use Triaminic Vapor Patch
Use Of Triaminic Vapor Patch Considered Risky. The U.S. Food and Drug Administration (FDA) today is warning consumers not to use the Triaminic Vapor Patch marketed by Novartis Consumer Health due to reports of serious adverse events associated with accidental ingestion by children. Novartis Consumer Health also announced … [Read more...] about FDA Warns Consumers Not to Use Triaminic Vapor Patch
Novartis Consumer Health Triaminic Vapor Patch Recall
Triaminic Vapor Patch Nationwide Recall. Novartis Consumer Health announced today it is conducting a nationwide voluntary recall of all Vapor Patch product marketed under the Triaminic brand due to the serious adverse health effects that could result if the product is ingested by the child removing the patch and chewing on … [Read more...] about Novartis Consumer Health Triaminic Vapor Patch Recall
Novartis recalls Triaminic Vapor Patch in U.S.
Canada warned that a Canadian child who chewed on a patch suffered a seizure. Novartis AG has recalled cough-suppressing Triaminic Vapor Patches in the United States, about three weeks after Health Canada warned that a Canadian child who chewed on a patch suffered a seizure. The Swiss drug company told consumers to stop using its … [Read more...] about Novartis recalls Triaminic Vapor Patch in U.S.
Cafergot Gets Warning
Cafergot Gets A New Black Box Warning From The U.S. FDA. FDA and Novartis strengthened the labeling, including a new BOXED WARNING and updates to the CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and CLINICAL PHARMACOLOGY sections of the prescribing information for ‘Cafergot’. Serious and/or life-threatening peripheral ischemia has … [Read more...] about Cafergot Gets Warning
